FKGK11

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-116018 1071000-98-0 C ₁₃ H ₁₃ F ₅ O 280.23 Phospholipase Metabolic Enzyme/Protease Please store the product under the recommended conditions in the Certificate of	O F F F F
5	Analysis.	

Product Data Sheet

BIOLOGICAL ACTIVITY Description FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis^{[1][2]}. IC_{so} & Target PLA2 In Vitro FKGK11 shows 99.4 ± 0.1% inhibition of GVIA iPLA2 and only 28 ± 1% for GV sPLA2 at 0.091 mole fraction^[1]. FKGK11 reduces adhesion, migration, and invasion of EOC (epithelial ovarian cancer) cells^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo FKGK11 shows a significant increase in the number of macrophages and degenerating fibres with disrupted myelin sheaths in cPLA2 GIVA-/- mice and C57BL/6 mice^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kokotos G, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.

[2]. Yan Xu, et al. Abstract 3525: Targeting Group VIA phospholipase A2 using small molecules for ovarian cancer treatment. Cancer Res (2011) 71 (8_Supplement): 3525.

[3]. López-Vales R, et al. Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain. 2008 Oct;131(Pt 10):2620-31.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA